nivolumab + ipilimumab + carboplatin + paclitaxel

This therapeutic regimen consists of the immune checkpoint inhibitors nivolumab and ipilimumab administered in combination with standard-of-care chemotherapy (carboplatin and paclitaxel). Nivolumab is a human IgG4 monoclonal antibody that blocks the programmed death-1 (PD-1) receptor, while ipilimumab is a human IgG1 monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Together, these immunotherapies aim to enhance the anti-tumor immune response by removing inhibitory signals on T-cells. Carboplatin is a platinum-based alkylating agent that interferes with DNA repair and synthesis, and paclitaxel is a taxane that stabilizes microtubules, thereby inhibiting cell division. This specific combination is being evaluated by Memorial Sloan Kettering Cancer Center in a Phase 1 pilot study for patients with advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer, specifically in the neoadjuvant and adjuvant settings to assess safety and tolerability.

Brand names

OpdivoYervoy

Other names

nivolumabipilimumabcarboplatinpaclitaxel